Effect of hepatobiliary disease, chronic hepatitis C and hepatitis B virus infections and interferon-α on porphyrin profiles in plasma, urine and faeces

Journal of Gastroenterology and Hepatology (Australia)

Volumn 15, Issue 2, 2000, Pages 192-201

  Gibson, Peter R ^a   Grant, Janine ^b   Cronin, Virginia ^b   Blake, Dennis ^b   Ratnaike, Sujiva ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Hepatitis B; Hepatitis C; Interferon ; Liver disease; Porphyria cutanea tarda; Porphyrins

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA INTERFERON; AMINOTRANSFERASE; BILIRUBIN; PORPHYRIN; RECOMBINANT ALPHA2B INTERFERON;

ARTICLE; BILIARY EXCRETION; BILIRUBIN BLOOD LEVEL; FECES ANALYSIS; HEPATITIS B; HEPATITIS C; HEPATOBILIARY DISEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; PORPHYRIA CUTANEA TARDA; PORPHYRIN METABOLISM; PREVALENCE; PRIORITY JOURNAL; URINALYSIS; VIRUS INFECTION;

EID: 0034102979     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2000.02065.x     Document Type: Article

References (33)

1. 1 Ostrowski J, Kosecki P, Martynska M, Milewski B. Urinary porphyrins in liver disease. Scand. J. Gastroenterol. 1984; 19: 862-6.
2. 2 DeRover CM, Rumini C, Tulpule PG. Urinary porphyrin pattern in liver damage. Food Chem. Toxicol. 1984; 22: 241-3.
3. 3 Rocchi E, Gibertini P, Santunione V, Balli F, Ventura E. Faecal and urinary coproporphyrin isomers in biliary atresia and neonatal hepatitis. Ric. Clin. Lab. 1980; 10: 501-9.
4. 4 Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998; 27: 1661-9.
5. 5 Stoelzel U, Koestler E, Koszka C et al. Low prevalence of hepatitis C virus infection in porphyria cutanea tarda in Germany. Hepatology 1995; 21: 1500-3.
6. 6 Gibson PR, Ratnaike S, Blake D, Sinickas V. Porphyria cutanea tarda and hepatitis C. Med. J. Aust. 1995; 162: 54.
7. 7 Fargion S, Piperno A, Cappellini MD et al. Hepatitis C virus and porphyria cutanea tarda: Evidence of a strong association. Hepatology 1992; 16: 1322-6.
8. 8 Herrero C, Vicente A, Bruguera M et al. Is hepatitis C infection a trigger of porphyria cutanea tarda? Lancet 1993; 341: 788-9.
9. 9 DeCastro M, Sanchez J, Herrera JF et al. Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda. Hepatology 1993; 17: 551-7.
10. 10 Navas S, Bosch O, Castillo I, Marriott E, Carreno V. Porphyria cutanea tarda and hepatitis C and B viruses infection: A retrospective study. Hepatology 1995; 21: 279-84.
11. 11 Antonov K, Krastev Z, Teoharov P et al. Hepatitis C virus infection: A possible promoting agent in porphyria cutanea tarda. Ital. J. Gastroenterol. 1996; 28: 482-6.
12. 12 Lamoril J, Andant C, Bogard C et al. Epidemiology of hepatitis C and G in sporadic and familial porphyria cutanea tarda. Hepatology 1998; 27: 848-52.
13. 13 Stuart KA, Busfield F, Jazwinska EC et al. The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. J. Hepatol. 1998; 28: 404-9.
14. 14 O'Reilly FM, Darby C, Fogarty J et al. Porphyrin metabolism in hepatitis C infection. Photodermatol. Photoimmunol. Photomed. 1996; 12: 31-3.
15. 15 Armas-Merino R, Wolff C, Parraguez A, Soto JR. Excrecion de porfirinas e infeccion cronica por virus C de la hepatitis. Rev. Med. Chil. 1997; 125: 279-82.
16. 16 Moran MJ, Fontanellas A, Brudieux E et al. Hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda patients: The influence of virus C infection. Hepatology 1998; 27: 584-9.
17. 17 Nomura N, Zolla-Pazner S, Simberkoff M, Kim M, Sassa S, Lim HW. Abnormal serum porphyrin levels in patients with the acquired immunodeficiency syndrome with or without hepatitis C virus infection. Arch. Dermatol. 1996; 132: 906-10.
18. 18 O'Connor WJ, Murphy GM, Darby C et al. Porphyrin abnormalities in acquired immunodeficiency syndrome. Arch. Dermatol. 1996; 132: 1443-7.
19. 19 Cribier B, Rey D, Uhl G et al. Abnormal urinary coproporphyrin levels in patients infected by hepatitis C virus with or without human immunodeficiency virus. A study of 177 patients. Arch. Dermatol. 1996; 132: 1448-52.
20. 20 Stanley LA, Adams DJ, Balkwill FR, Griffin D, Wolf CR. Differential effects of recombinant interferon alpha on constitutive and inducible cytochrome P450 isozymes in mouse liver. Biochem. Pharmacol. 1991; 42: 311-20.
21. 21 Hrelia P, Morotti M, Vignagni F et al. The modulating activity of interferon on benzo (a) pyrene bioactivation and clastogenesis in mice. Pharmacol. Toxicol. 1994; 74: 249-54.
22. 22 Takikawa H, Yamazaki R, Shoji S, Kiyake K, Yamanaka M. Normalization of urinary porphyrin level and disappearance of skin lesions after successful interferon therapy in a case of chronic hepatitis C complicated with porphyria cutanea tarda. J. Hepatol. 1995; 22: 249-50.
23. 23 Sheikh MY, Wright RA, Burruss JB. Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferon-alpha therapy in a case of chronic hepatitis C. Dig. Dis. Sci. 1998; 43: 529-33.
24. 24 Okana J, Horie Y, Kawasaki H, Kondo M. Interferon treatment of porphyria cutanea tarda associated with chronic hepatitis type C. Hepatogastroenterology 1997; 44: 525-8.
25. 25 Gibson PR, Gibson RN, Donlan JD, Ditchfield MR, Bhathal PS. Duplex Doppler ultrasound of the ligamentum teres and portal vein: A clinically useful adjunct in the evaluation of patients with known or suspected chronic liver disease or portal hypertension. J. Gastroenterol. Hepatol. 1991; 6: 55-9.
26. 26 Woods JS, Martin MD, Leroux BG. Validity of spot urine samples as a surrogate measure of 24-hour porphyrin excretion rates. Evaluation of diurnal variations in porphyrin, mercury, and creatinine concentrations among subjects with very low occupational mercury exposure. J. Occupat. Environ. Med. 1998; 40: 1090-101.
27. 27 Blake D, Poulos V, Rossi R. Diagnosis of porphyria: Recommended methods for peripheral laboratories; plasma and whole blood total porphyrin: Fluorometric method. Clin. Biochem. Rev. 1992; 13 (Suppl. 1): S12-13.
28. 28 Lockwood WH, Poulos V, Rossi E, Curnow DH. A rapid procedure for faecal porphyrin assay. Clin. Chim. Acta 1984; 139: 55-63.
29. 29 Nuttall KL, Pingree SS, Ashwood ER. Reference intervals for 24-hour and random urine porphyrins. Ann. Clin. Lab. Sci. 1996; 26: 313-22.
30. 30 Poulos V, Lockwood WH. A rapid method for estimating red blood cell porphyrin. Int. J. Biochem. 1980; 12: 1049-50.
31. 31 Lim CK, Peters TJ. Urine and faecal porphyrin profiles by reversed phase high-performance liquid chromatography in the porphyrias. Clin. Chim. Acta 1984; 139: 55-63.
32. 32 Ratnaike S, Blake D. The diagnosis and follow up of porphyria. Pathology 1995; 27: 142-53.
33. 33 Young GP, St John JB, Rose I, Blake D. Haem in the gut. Part II. Faecal excretion of haem and haem-derived porphyrins and their detection. J. Gastroenterol. Hepatol. 1990; 5: 194-203.